StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$15.29−2.21 (-12.66%)

Close on Nov 18, 2026Market cap $83.97MP/E –Yield –

InMed Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

InMed Pharmaceuticals's operating income for the twelve months ending Sep 30, 2023 was -$6.97M. For fiscal 2023 it was -$7.95M.

Annual operating income

PeriodPeriod endValueChange
FY2023Jun 30, 2023-$7.95M–
FY2022Jun 30, 2022-$18.60M–
FY2021Jun 30, 2021-$10.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2024CQ3 2023Sep 30, 2023-$2.54M–
Q4 FY2023CQ2 2023Jun 30, 2023-$338.39K–
Q3 FY2023CQ1 2023Mar 31, 2023-$2.00M–
Q2 FY2023CQ4 2022Dec 31, 2022-$2.10M–
Q1 FY2023CQ3 2022Sep 30, 2022-$3.51M–
Q4 FY2022CQ2 2022Jun 30, 2022-$7.87M–
Q3 FY2022CQ1 2022Mar 31, 2022-$3.48M–
Q2 FY2022CQ4 2021Dec 31, 2021-$4.28M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.97M–
Q4 FY2021CQ2 2021Jun 30, 2021-$3.26M–
Q3 FY2021CQ1 2021Mar 31, 2021-$3.10M–
Q2 FY2021CQ4 2020Dec 31, 2020-$2.24M–

More InMed Pharmaceuticals figures

See a number that looks wrong?